Mesoblast Stock Z Score
| MESO Stock | USD 10.18 0.15 1.45% |
Mesoblast | Z Score |
Mesoblast Company Z Score Analysis
Mesoblast's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Mesoblast Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Mesoblast is extremely important. It helps to project a fair market value of Mesoblast Stock properly, considering its historical fundamentals such as Z Score. Since Mesoblast's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mesoblast's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mesoblast's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Mesoblast has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Mesoblast Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in z score category among its peers.
Mesoblast Current Valuation Drivers
We derive many important indicators used in calculating different scores of Mesoblast from analyzing Mesoblast's financial statements. These drivers represent accounts that assess Mesoblast's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mesoblast's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.6B | 1.8B | 576.2M | 609.5M | 669.0M | 635.5M | |
| Enterprise Value | 2.5B | 1.8B | 623.0M | 655.1M | 724.9M | 688.7M |
Mesoblast ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mesoblast's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mesoblast's managers, analysts, and investors.Environmental | Governance | Social |
Mesoblast Institutional Holders
Institutional Holdings refers to the ownership stake in Mesoblast that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Mesoblast's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Mesoblast's value.| Shares | Rockbridge Investment Management, Llc | 2024-09-30 | 49.1 K | Lpl Financial Corp | 2024-06-30 | 30 K | Xy Capital Ltd | 2024-09-30 | 29.9 K | Bank Of America Corp | 2024-06-30 | 20.1 K | Xtx Topco Ltd | 2024-06-30 | 15.1 K | Chapin Davis Inc | 2024-09-30 | 15 K | Rathbone Brothers Plc | 2024-06-30 | 14 K | Millennium Management Llc | 2024-06-30 | 13.5 K | Pine Valley Investments Ltd Liability Co | 2024-06-30 | 11.7 K | Group One Trading, Lp | 2024-06-30 | 227.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 167.2 K |
Mesoblast Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 1.23 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 1.38 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 199.84 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | (47.42 M) | ||||
| EBITDA | (62.82 M) | ||||
| Net Income | (87.96 M) | ||||
| Cash And Equivalents | 85.5 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 118.92 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (48.46 M) | ||||
| Short Ratio | 6.69 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 73 | ||||
| Beta | 2.34 | ||||
| Market Capitalization | 1.14 B | ||||
| Total Asset | 669.15 M | ||||
| Retained Earnings | (908.76 M) | ||||
| Working Capital | 13.22 M | ||||
| Current Asset | 88.82 M | ||||
| Current Liabilities | 29.41 M | ||||
| Net Asset | 669.15 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Mesoblast
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.Moving together with Mesoblast Stock
Moving against Mesoblast Stock
| 0.85 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.85 | KURA | Kura Oncology | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.79 | BDRX | Biodexa Pharmaceticals Upward Rally | PairCorr |
| 0.7 | STOK | Stoke Therapeutics | PairCorr |
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Mesoblast Piotroski F Score and Mesoblast Valuation analysis. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.41) | Return On Assets (0.05) | Return On Equity (0.18) |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.